Posts by: Margarida Azevedo, MSc

Margarida Azevedo, MSc

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

March 16, 2020March 23, 2020

Veru Advances Prostate Cancer Therapy VERU-111 to Phase 2 Portion of Trial

News

Veru said it initiated the Phase 2 portion of a clinical trial testing the safety and effectiveness of its investigational therapy, VERU-111, in men with metastatic castration-resistant prostate cancer (mCRPC) ... Read more

February 17, 2020February 17, 2020

eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest

News

Daily treatment with a low dose of eRapa, Emtora Biosciences‘ new formulation of the therapeutic agent rapamycin, was safe and well tolerated, and led to immune system cell boosting in ... Read more

May 12, 2016May 12, 2016

Testosterone Replacement Therapy Not Seen to Raise Prostate Cancer Risk

News

Researchers at NYU Langone Medical Center, looking into the controversial association between testosterone replacement therapy (TRT) and prostate cancer risk, found that TRT had no impact on cancer risk but did help to ... Read more

May 5, 2016May 5, 2016

Researchers Identify Potential Cause for Prostate Cancer Treatment Resistance Among African-American Men, New Possible Therapeutic Strategy

News

Researchers at the Roswell Park Cancer Institute (RPCI) recently demonstrated that mitochondrial dysfunction may help explain the greater incidence of prostate cancer and poorer responses to conventional therapies in African ... Read more

May 3, 2016May 3, 2016

Specific Gene, PLK1, Promotes the Spread of Prostate Cancer, Study Finds

News

Researchers at the Virginia Commonwealth University School of Medicine found that Polo-like kinase 1 (PLK1) gene overexpression promotes oncogenic transformation and the migration of prostate cancer cells. The findings point the way ... Read more

April 28, 2016April 28, 2016

Exiqon Announces Validation of a Biomarker Able to Distinguish Aggressive from Low-Risk Prostate Cancers

News

Exiqon Life Sciences announced the publication of a study detailing the validation of its prognostic microRNA biomarker profile, an non-invasive way of distinguishing patients with aggressive prostate cancers from those ... Read more

April 21, 2016April 21, 2016

ExoDx Prostate Non-Invasive Test May Eliminate Unnecessary Prostate Biopsies, Study Says

News

Exosome Diagnostics revealed positive clinical results evaluating its urine-based prostate cancer liquid biopsy test called ExoDx Prostate (IntelliScore). The study, “A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at ... Read more

April 19, 2016November 18, 2016

‘Active Surveillance’ of Lower Risk Prostate Cancers Seen as Safe Approach in Study, But Only in Certain Patients

News

Researchers analyzing clinical and pathological outcomes in men with low- and intermediate-risk prostate cancer under “active surveillance” found that — despite close monitoring — metastatic disease develops in about 3 ... Read more

April 12, 2016April 12, 2016

Androgen Deprivation Therapy in Prostate Cancer May Counter Immunotherapy, Raising Risk of Relapse

News

UT Southwestern Medical Center researchers have shown that medical androgen deprivation therapy, commonly used in combination with promising immunotherapies, can actually suppress the immune response and block the efficacy of the immunotherapy. ... Read more

March 31, 2016March 31, 2016

Recurrent Prostate Cancer Survival Rates Seen to Greatly Improve Through Radical Surgery

News

A retrospective study, using a national database, analyzed data from patients with prostate cancer and found that a complex surgical procedure — salvage radical prostatectomy (SRP) — can greatly improve long-term survival outcomes in those ... Read more